United States Neuropathic Pain Market Set for Strong Growth as Novel Therapies and Investments Reshape the Future of Pain Management 2025 | Top key players - Pfizer Inc., AdvaCare Pharma, Eli Lilly and Company.

Market Size and Growth:

The Neuropathic Pain Market size reached US$ 8.44 Billion in 2024 and is expected to reach US$ 18.45 Billion by 2033, growing at a CAGR of 8.9 % during the forecast period 2025-2033.

The Neuropathic Pain Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Neuropathic Pain market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for growth.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/neuropathic-pain-market?sz

The Neuropathic Pain Market refers to the healthcare segment focused on diagnosing, managing, and treating chronic pain caused by nerve damage or dysfunction. It includes pharmaceuticals, medical devices, and emerging therapies aimed at alleviating conditions such as diabetic neuropathy, postherpetic neuralgia, and spinal cord injuries, with growing demand driven by rising prevalence and advancements in pain management solutions.

Recent Key Developments of United States (U.S):

Non-Opioid Analgesic Approval: The FDA approved Journavx (suzetrigine) oral tablets in January 2025 for moderate to severe acute pain. While not specifically for chronic neuropathic pain, its mechanism of action as a selective NaV1.8 sodium channel inhibitor is being explored for broader applications, including peripheral neuropathic pain and painful diabetic peripheral neuropathy.

Fibromyalgia Treatment: In August 2025, the FDA approved Tonmya (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia. This marks a new medication specifically for this condition, which is often associated with widespread neuropathic pain.

Growing Market Value: The U.S. neuropathic pain market is projected to reach approximately $5.92 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 7.81% from 2025 to 2034. This growth is driven by the increasing prevalence of chronic diseases like diabetes and cancer that lead to neuropathic pain.

Focus on Non-Pharmacological Treatments: There is a growing trend and ongoing research into non-pharmacological interventions, such as neurostimulation techniques (e.g., Deep Brain Stimulation and Transcranial Magnetic Stimulation) and gene therapies, as alternative or complementary approaches to pain management.

Personalized Medicine: The market is shifting towards personalized treatment approaches, utilizing genetic insights and biomarkers to tailor pain management strategies for individual patients. This trend aims to improve efficacy and reduce side effects compared to traditional broad-spectrum medications.

Key Players:

Pfizer Inc.
AdvaCare Pharma
Eli Lilly and Company.
Vertex Pharmaceuticals
Abbott
Medtronic
Nevro Corp.
Grünenthal
Teva Pharmaceuticals Inc.
Sun Pharmaceutical Industries Ltd.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=neuropathic-pain-market

Market Segmentation:

By Type: Diabetic Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Post-Herpetic Neuralgia, Trigeminal Neuralgia, Spinal Stenosis, Others.

By Treatment Type: Drug Class, Devices.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/neuropathic-pain-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Neuropathic Pain market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Neuropathic Pain Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Neuropathic Pain market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Neuropathic Pain Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Neuropathic Pain Market in 2025?
◆ What is the projected growth rate of the Neuropathic Pain Market through 2033?
◆ Who are the key players in the Neuropathic Pain Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.